Arendt advises Bain Capital on STADA exit to CapVest Partners and continued stake in the business
Arendt & Medernach advised Bain Capital on all Luxembourg law aspects of its exit from STADA Arzneimittel AG through the sale of a majority stake to funds managed by CapVest Partners LLP, while supporting Bain Capital's reinvestment and continued participation in the business as a minority shareholder.
Experts involved in the Deal
Corporate Law, Mergers & Acquisitions
- Sébastien Binard
- Romain Scellier
- Tania Tossa
- Julien Leroy
Tax
- Jan Neugebauer
- Stéphanie Viot
- Thomas Klein
Arendt advised Bain Capital, one of the world’s leading private investment firms, on all Luxembourg law aspects of its exit from STADA Arzneimittel AG through the sale of a majority stake to funds managed by CapVest Partners LLP, while supporting Bain Capital’s reinvestment and continued participation in the business as a minority shareholder.
Based in Bad Vilbel, Germany, STADA has grown into one of Europe’s most recognised pharmaceutical groups, built around three core business lines: branded generics, consumer health and specialty pharmaceuticals. The group employs around 11,700 people across its global operations, generates revenues in excess of €4 billion and reaches patients and consumers in some 120 markets—a platform substantially shaped under Bain Capital’s ownership following its acquisition of the company in 2017 in one of Europe’s landmark leveraged buyouts.
Bain Capital’s decision to reinvest and retain a minority stake in STADA alongside CapVest Partners reflects its continued conviction in the company’s long-term growth trajectory and the strength of the platform it has helped build over the past seven years.
